Table 4.
Summary of the drug classes assessed for antinociceptive effect in animal models of injury-related or pathological persistent pain.
| Drug class | No. of studies | No. of nested comparisons |
|---|---|---|
| CB2 receptor agonist | 75 | 299 |
| CB1 receptor agonist | 88 | 281 |
| Nonselective cannabinoid receptor agonist | 71 | 230 |
| FAAH inhibitor | 57 | 217 |
| PPAR-alpha agonist | 40 | 121 |
| THC | 16 | 69 |
| Anandamide transport inhibitor | 18 | 64 |
| CBD | 17 | 63 |
| Monoacylglycerol lipase inhibitor | 23 | 58 |
| FABP inhibitor | 3 | 31 |
| Unknown mechanism of action | 6 | 25 |
| NAAA inhibitor | 4 | 20 |
| CB1 receptor inverse agonist | 7 | 19 |
| Diacylglycerol lipase inhibitor | 3 | 14 |
| Dual FAAH/MGL inhibitor | 4 | 10 |
| CB1 receptor PAM | 1 | 5 |
| FAAH inhibitor/TRPV1 agonist | 1 | 5 |
| CB2 receptor inverse agonist | 2 | 4 |
| ABHD6 inhibitor | 1 | 3 |
| FAAH inhibitor/TRPA1 agonist | 1 | 2 |
| PPAR-gamma antagonist | 1 | 2 |
| GPR55 agonist | 1 | 1 |
| Hemp oil | 1 | 1 |
ABHD6, abhydrolase domain containing 6; CB1, cannabinoid type 1; CB2, cannabinoid type 2; CBD, cannabidiol; FABP, fatty acid-binding protein; FAAH, fatty acid amide hydrolase; MGL, monoacylglycerol lipase; NAAA, N-acylethanolamine-hydrolysing acid amidase; PPAR, peroxisome proliferator-activated receptor; PAM, positive allosteric modulator; TRPV1, transient receptor potential vanilloid receptor 1; TRPA1, transient receptor potential ankyrin 1; THC, delta-9 tetrahydrocannabinol.